1,906 Shares of Elevance Health, Inc. $ELV Acquired by MBL Wealth LLC

MBL Wealth LLC bought a new stake in shares of Elevance Health, Inc. (NYSE:ELV) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,906 shares of the company’s stock, valued at approximately $741,000.

A number of other hedge funds have also recently modified their holdings of the business. BlackRock Inc. purchased a new position in Elevance Health during the 2nd quarter valued at $7,344,424,000. Bank of New York Mellon Corp purchased a new stake in Elevance Health in the second quarter worth $1,246,349,000. Legal & General Group Plc purchased a new stake in Elevance Health in the second quarter worth $688,469,000. Amundi lifted its position in shares of Elevance Health by 145.7% during the first quarter. Amundi now owns 2,693,664 shares of the company’s stock worth $788,570,000 after purchasing an additional 1,597,497 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Elevance Health during the second quarter worth $591,084,000. Institutional investors own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ELV shares. Wells Fargo & Company lowered their target price on shares of Elevance Health from $492.00 to $473.00 and set an “overweight” rating for the company in a research note on Thursday, July 16th. Morgan Stanley raised their price target on shares of Elevance Health from $404.00 to $449.00 and gave the stock an “equal weight” rating in a research note on Thursday. Barclays lifted their price objective on shares of Elevance Health from $469.00 to $472.00 and gave the company an “overweight” rating in a report on Thursday. Royal Bank Of Canada boosted their price objective on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research report on Thursday. Finally, Mizuho set a $490.00 target price on shares of Elevance Health in a research note on Friday. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $455.57.

Elevance Health Stock Down 1.2%

Elevance Health stock traded down $5.23 during midday trading on Friday, hitting $440.05. 1,173,816 shares of the company’s stock were exchanged, compared to its average volume of 1,329,873. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.47. The company has a market cap of $95.43 billion, a PE ratio of 18.77, a P/E/G ratio of 2.32 and a beta of 0.70. The firm has a 50-day moving average of $408.32 and a two-hundred day moving average of $390.89. Elevance Health, Inc. has a 12 month low of $274.84 and a 12 month high of $450.69.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. During the same quarter in the previous year, the business posted $6.03 EPS. The company’s quarterly revenue was up .7% compared to the same quarter last year. As a group, analysts expect that Elevance Health, Inc. will post 27.09 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s dividend payout ratio (DPR) is presently 29.34%.

Insider Buying and Selling

In related news, CFO Mark Kaye sold 10,584 shares of the business’s stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer owned 19,919 shares of the company’s stock, valued at $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.34% of the stock is owned by company insiders.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.